Empagliflozin
| Evidence Level: L5 | Predicted Indications: 50 |
Quick Overview
| Item | Value |
|---|---|
| Drug Name | Empagliflozin |
| DrugBank ID | DB09038 |
| Brand Names (EU) | Jardiance |
| Evidence Level | L5 |
| Predicted Indications | 50 |
| Top Prediction Score | 99.06% |
Approved Indication (EMA)
Type 2 diabetes mellitus Jardiance is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when metformin is considered inappropriate due to intolerance in addition to other medicinal products for the treatment of diabetes For study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studie
Predicted New Indications
TxGNN model predictions for potential drug repurposing:
| Rank | Indication | Score | Source |
|---|---|---|---|
| 1 | classic stiff person syndrome | 99.06% | DL |
| 2 | focal stiff limb syndrome | 99.06% | DL |
| 3 | opsismodysplasia | 99.03% | DL |
| 4 | thiamine-responsive dysfunction syndrome | 98.99% | DL |
| 5 | diabetes mellitus (disease) | 98.95% | DL |
| 6 | drug-induced localized lipodystrophy | 98.46% | DL |
| 7 | centrifugal lipodystrophy | 98.39% | DL |
| 8 | pressure-induced localized lipoatrophy | 98.34% | DL |
| 9 | idiopathic localized lipodystrophy | 98.25% | DL |
| 10 | pancreatic agenesis | 98.07% | DL |
| 11 | autoimmune oophoritis | 92.37% | DL |
| 12 | type 1 diabetes mellitus | 92.30% | DL |
| 13 | homozygous familial hypercholesterolemia | 88.13% | DL |
| 14 | polymicrogyria, perisylvian, with cerebellar hypoplasia and arthrogryposis | 72.71% | DL |
| 15 | retinal dystrophy with or without extraocular anomalies | 72.35% | DL |
| 16 | diabetes mellitus, insulin-dependent, X-linked, susceptibility to | 71.83% | DL |
| 17 | Charcot-Marie-Tooth disease, demyelinating, type 1G | 68.69% | DL |
| 18 | myopia X-linked | 68.03% | DL |
| 19 | syndromic myopia | 65.73% | DL |
| 20 | atrial flutter (disease) | 64.23% | DL |
Showing top 20 of 50 predictions.
About TxGNN Predictions
Prediction Sources
| Source | Description |
|---|---|
| KG | Knowledge Graph - Network topology-based associations |
| DL | Deep Learning - Neural network score prediction |
Evidence Levels
| Level | Definition |
|---|---|
| L1 | Multiple Phase 3 RCTs / Systematic Reviews |
| L2 | Single RCT or multiple Phase 2 trials |
| L3 | Observational studies / Large case series |
| L4 | Preclinical / Mechanistic / Case reports |
| L5 | AI prediction only (current) |
Clinical Validation Needed
Research Use Only: These predictions are computational hypotheses that require clinical validation. They should NOT be used for clinical decision-making.
Next Steps for Validation
- Literature Review: Search PubMed for existing evidence
- Clinical Trial Search: Check ClinicalTrials.gov for ongoing studies
- Mechanistic Analysis: Evaluate biological plausibility
- Preclinical Studies: Conduct in vitro/in vivo validation
- Clinical Trials: Design and conduct human studies
Data Access
- FHIR API:
/fhir/ClinicalUseDefinition/ - CSV Download: All Predictions
- GitHub: yao-care/EuTxGNN
Citation
If using this data, please cite:
@article{huang2023txgnn,
title={A foundation model for clinician-centered drug repurposing},
author={Huang, Kexin and others},
journal={Nature Medicine},
year={2023},
doi={10.1038/s41591-023-02233-x}
}
Disclaimer: This report is for research purposes only and does not constitute medical advice. Drug repurposing predictions require rigorous clinical validation before any therapeutic application.